US-based drug developer MyoKardia closed its series B round yesterday, raising $46m from investors including pharmaceutical company Sanofi.
Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences, BridgeBio, an unnamed affiliate of Cowen Group and an undisclosed public investment fund also participated in the funding round.
MyoKardia is developing treatments for genetic heart diseases, and will use the cash injection to advance its pipeline of potential therapies for hypertrophic and dilated cardiomyopathies, diseases that affect the muscle of the heart and…
